Global S&T Development Trend Analysis Platform of Resources and Environment
UK government invests in Livingston facility to bolster vaccine manufacturing capacity | |
admin | |
2020-08-05 | |
发布年 | 2020 |
语种 | 英语 |
国家 | 英国 |
领域 | 气候变化 ; 资源环境 |
正文(英文) |
Press release
UK government invests in Livingston facility to bolster vaccine manufacturing capacityUK government and Valneva confirm multi-million-pound up-front investment in Livingston manufacturing facility. ![]()
A manufacturing facility in Livingston, West Lothian, will be at the heart of efforts to produce a new coronavirus vaccine thanks to a multi-million-pound joint investment as part of an agreement in principle by the UK government to secure early access to 60 million doses of Valneva’s promising vaccine candidate. The joint investment, made between the UK government and global biotech company Valneva, will advance Scotland’s vaccine manufacturing capacity and support highly skilled jobs for scientists and technicians at the West Lothian site. Currently more than 100 people are employed at the facility with a quarter of those working directly on a coronavirus vaccine. Researchers working on the vaccine’s manufacture are expected to grow in number by a further 75 as production gets underway. If Valneva’s vaccine is proven to be safe and effective in clinical trials, the expanded Livingston facility could potentially supply up to 100 million vaccine doses to the UK and internationally. The committed investment will be highlighted by UK Business Secretary Alok Sharma on a visit to Valneva’s facility in West Lothian today (Wednesday 5 August), ensuring the vaccine can be manufactured at scale to protect millions of people in priority groups, such as health and social care workers and those at increased health risk, across the United Kingdom if clinical trials are successful. The Business Secretary will witness first-hand the ground-breaking work already taking place at the Livingston manufacturing facility and hear about the significant efforts being made to increase capacity at the site. Welcoming the agreement ahead of his visit, Business Secretary Alok Sharma said:
Secretary of State for Scotland Alister Jack said:
Chair of the Vaccine Taskforce Kate Bingham said:
Chief Financial Officer of Valneva David Lawrence said:
The Livingston facility is in addition to the new Vaccines Manufacturing and Innovation Centre (VMIC) which is currently under construction in Oxfordshire thanks to further investment from the UK government. When completed in summer 2021, the facility will have flexible capacity to manufacture millions of vaccine doses at scale. The UK government has also reached an existing global licensing agreement signed with AstraZeneca and the University of Oxford to research, develop and manufacture 100 million doses of a COVID-19 vaccine for the British public, as well as a partnership with BioNTech and Pfizer for 30 million doses if their trials are successful. And just last week, a deal was reached with GSK and Sanofi to secure 60 million doses of their vaccine candidate, further boosting the UK’s chances of receiving access to an effective immunisation. A further £40 million government investment has been given to Imperial College London to develop their vaccine candidate, which is now being trialled with more than 200 people across 6 locations. Notes to editorsVLA2001 is a highly purified, inactivated vaccine candidate against the SARS-CoV-2 virus that uses manufacturing technology from Valneva’s Japanese Encephalitis Vaccine. The inactivation process preserves the structure of the virus’ S protein and is expected to induce a strong immune response. The 4 different vaccine classes that the government has secured to date for the UK are:
In addition the UK has secured rights to AstraZeneca’s antibody treatment to neutralise the virus which can be used both as a short term prophylactic for those people who cannot receive vaccines (for example cancer and immunosuppressed patients) and front line workers exposed to the virus, as well as a treatment for infected patients.
Published 5 August 2020
|
URL | 查看原文 |
来源平台 | Department for Business, Energy & Industrial Strategy |
文献类型 | 新闻 |
条目标识符 | http://119.78.100.173/C666/handle/2XK7JSWQ/285976 |
专题 | 气候变化 资源环境科学 |
推荐引用方式 GB/T 7714 | admin. UK government invests in Livingston facility to bolster vaccine manufacturing capacity. 2020. |
条目包含的文件 | 条目无相关文件。 |
个性服务 |
推荐该条目 |
保存到收藏夹 |
查看访问统计 |
导出为Endnote文件 |
谷歌学术 |
谷歌学术中相似的文章 |
[admin]的文章 |
百度学术 |
百度学术中相似的文章 |
[admin]的文章 |
必应学术 |
必应学术中相似的文章 |
[admin]的文章 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论